Beclometasone pressurised metered-dose inhaler - Chiesi

Drug Profile

Beclometasone pressurised metered-dose inhaler - Chiesi

Alternative Names: BDP Modulite®; Beclazone Modulite; Beclazone Modulite Easi-Breathe; Beclojet 250 HFA; Beclometasone HFA inhalation - Chiesi; Beclometasone Modulite; Beclometasone pMDI; Beclomethasone HFA inhalation - Chiesi; Beclomethasone hydrofluoroalkane inhalation - Chiesi; Beclomethasone Modulite; Clenil Modulite

Latest Information Update: 13 Oct 2009

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 23 Mar 2017 Chiesi plans a phase II trial for Asthma (NCT03084718)
  • 16 Sep 2009 Efficacy data from a clinical trial in Asthma presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 24 Jul 2006 Launched for Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top